Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02684630 · ClinicalTrials.gov registry record · NA

Trima Accel® System Post Count Algorithm Study

A NA study, sponsored by Terumo BCT.

Completed
Registry status
NA
Development phase
131
Enrollment target

NCT02684630: Completed NA study, sponsored by Terumo BCT.

NCT02684630 is a NA study that has completed, run by Terumo BCT. The registered enrollment target is 131 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02684630, a NA study, has completed, sponsored by Terumo BCT.

COMPLETED
Registry status
NA
Development phase
131 participants
Enrollment target

Study Summary

The purpose of this study is to optimize collected platelet yields in single and double platelet collections, while maintaining donor postplatelet count of \>100,000/µL.

Primary Outcome

The primary endpoint for this study was the postprocedure participant platelet count for participants who have completed a single or double platelet collection. A procedure was a success if the participant's postprocedure platelet count was ≥ 100,000 platelets/μL. A procedure was a failure if the participant's postprocedure platelet count was \< 100,000 platelets/μL.

Interventions

  • DEVICE Trima Accel System

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2016-01-28
Est. Completion 2016-05-28
Phase NA
Terumo BCT

12 total trials

What the finished NCT02684630 record still lists

NCT02684630 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 1 intervention - of which Trima Accel System is the first listed.

NCT02684630 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02684630 about?

NCT02684630 is a clinical study titled "Trima Accel® System Post Count Algorithm Study". The purpose of this study is to optimize collected platelet yields in single and double platelet collections, while maintaining donor postplatelet count of \>100,000/µL.

What is the current status of trial NCT02684630?

This trial is currently completed. It is a NA study. The enrollment target is 131 participants. The study started on 2016-01-28. Estimated completion is 2016-05-28.

What interventions are being tested in trial NCT02684630?

The interventions under investigation include: Trima Accel System (DEVICE).

Who is sponsoring clinical trial NCT02684630?

This trial is sponsored by Terumo BCT, which has 12 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02684630's enrollment target sits among peer trials

131 732nd of 2000 higher than 1,268 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03051464 · 131 participants · Phase 2

    No Surgery Trial / Two Dose-escalation Strategies

  • NCT04301843 · 131 participants · Phase 2

    Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

  • NCT04748549 · 131 participants · NA

    Intraoperative VR for Older Patients Undergoing TKA

  • NCT05951179 · 131 participants · Phase 2

    Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02684630, the US trial registry maintained by the National Library of Medicine. NCT02684630 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.